Difference between revisions of "Team:DTU-Denmark"

(now with pictures)
Line 15: Line 15:
 
body {background-color:white; }
 
body {background-color:white; }
 
#bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; }
 
#bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; }
 
 
 
/***************************************************** CONTENT OF THE PAGE ****************************************************/
 
 
/* Wrapper for the content */
 
.igem_2017_content_wrapper {
 
width: 81%;
 
margin: 2%;
 
display:block;
 
float:left;
 
background-color:white;
 
font-family:Tahoma, Geneva, sans-serif;
 
}
 
 
 
/********************************* HTML STYLING  *********************************/
 
 
/* styling for the titles h1 h2 */
 
.igem_2017_content_wrapper h1, .igem_2017_content_wrapper h2 {
 
padding:5px 15px;
 
border-bottom: 0px;
 
color: #3399ff;
 
}
 
 
 
/* styling for the titles  h3 h4 h5 h6*/
 
.igem_2017_content_wrapper h3, .igem_2017_content_wrapper h4, .igem_2017_content_wrapper h5, .igem_2017_content_wrapper h6 {
 
padding:5px 15px;
 
border-bottom:0px;
 
color: #000000; 
 
}
 
 
 
/* font and text */
 
.igem_2017_content_wrapper p {
 
padding: 0px 15px;
 
font-size: 13px;
 
}
 
 
/* Links */
 
.igem_2017_content_wrapper a {
 
font-weight: bold;
 
text-decoration: underline;
 
text-decoration-color: #3399ff;
 
color:  #3399ff;
 
-webkit-transition: all 0.4s ease;
 
-moz-transition: all 0.4s ease;
 
-ms-transition: all 0.4s ease;
 
-o-transition: all 0.4s ease;
 
transition: all 0.4s ease;
 
}
 
 
/* hover for the links */
 
.igem_2017_content_wrapper a:hover {
 
text-decoration:none;
 
color:#000000;
 
}
 
 
/* non numbered lists */
 
.igem_2017_content_wrapper ul {
 
padding:0px 20px;
 
font-size: 13px;
 
font-family:Tahoma, Geneva, sans-serif;
 
}
 
 
/* numbered lists */
 
.igem_2017_content_wrapper ol {
 
padding:0px;
 
font-size: 13px;
 
font-family:Tahoma, Geneva, sans-serif;
 
}
 
 
/* Table */
 
.igem_2017_content_wrapper table {
 
width: 97%;
 
margin:15px 10px;
 
border: 1px solid #d3d3d3;
 
border-collapse: collapse;
 
}
 
 
/* table cells */
 
.igem_2017_content_wrapper  td {
 
padding: 10px;
 
vertical-align: text-top;
 
border: 1px solid #d3d3d3;
 
border-collapse: collapse;
 
}
 
 
/* table headers */
 
.igem_2017_content_wrapper th {
 
padding: 10px;
 
vertical-align: text-top;
 
border: 1px solid #d3d3d3;
 
border-collapse: collapse;
 
background-color:#f2f2f2;
 
}
 
 
 
/**********************************LAYOUT CLASSES **********************************/
 
 
/* general class for column divs */
 
.igem_2017_content_wrapper .column  {
 
padding: 10px 0px;
 
float:left;
 
}
 
 
/* class for a full width column */
 
.column .full_size {
 
width:100%;
 
}
 
 
/* styling for images in a full width column*/
 
.column.full_size img {
 
width:97%;
 
padding: 10px 15px;
 
}
 
 
/* class for a half width column */
 
.column.half_size {
 
width: 50%;
 
}
 
/* styling for images in a half width column*/
 
.column.half_size img {
 
width: 94.5%;
 
padding: 10px 15px;
 
}
 
 
 
 
 
/********************************* SUPPORT CLASSES ********************************/
 
 
/* class that clears content below*/
 
.igem_2017_content_wrapper .clear {
 
clear:both;
 
}
 
 
 
/* adds extra spacing when clearing content */
 
.igem_2017_content_wrapper  .clear.extra_space {
 
height: 30px;
 
}
 
 
 
/* highlight class, makes content slightly smaller */
 
.igem_2017_content_wrapper .highlight {
 
margin: 0px 15px;
 
padding: 15px 0px;
 
}
 
 
 
/* highlight class, adds a gray background */
 
.igem_2017_content_wrapper .highlight.gray {
 
background-color: #f2f2f2;
 
}
 
 
/* highlight with decoration blue line on top */
 
.igem_2017_content_wrapper .highlight.blue_top {
 
    border-top: 4px solid #3399ff;
 
}
 
 
/* highlight with a full blue border decoration */
 
.igem_2017_content_wrapper .highlight.blue_border {
 
    border: 4px solid  #3399ff;
 
}
 
 
 
/* button class */
 
.igem_2017_content_wrapper .button{
 
max-width: 35%;
 
margin: 30px auto;
 
padding: 12px 10px;
 
    background-color: #3399ff;
 
    text-align: center;
 
  color: #ffffff;
 
-webkit-transition: all 0.4s ease;
 
-moz-transition: all 0.4s ease;
 
-ms-transition: all 0.4s ease;
 
-o-transition: all 0.4s ease; transition: all 0.4s ease; 
 
}
 
 
/* styling for button on hover */
 
.igem_2017_content_wrapper .button:hover{
 
background-color: #3399ff;
 
    color: #000000;
 
}
 
  
  

Revision as of 09:21, 13 July 2017

Snakebite Detectives

iGEM 2017

The most neglected tropical disease

Project description

Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.

One of the major problems related to treatment of snake bites concerns the lack of identification of the snake. When bitten, it is difficult for most people to remember details about the snake, which makes it almost impossible to confidently administer the correct specific antivenom. Currently, if the snake cannot be identified, multispecies antivenom is used in a consequently higher dose leading to more severe side effects. By solving the venom identification problem it could potentially increase the survival rate of snake bite victims. This is due to decreased diagnosis time and less amount of antivenom necessary for treatment, thereby causing fewer adverse reactions in the patient [3].

We aim to create a novel diagnostic platform by using synthetic biology derived protease activity assay to identify specific venom enzymes that, by developing suitable substrates, can investigate the relative composition of specific venom components in a blood sample. Our goal is to create a diagnostic tool that would make it possible for a clinician to quickly determine which antivenom is necessary, or if it is necessary at all.



References:

[1] Chippaux JP (1998). Snake-bites: appraisal of the global situation. Bulletin of the World Health Organization, 76(5),515-24.
[2] Gutiérrez JM, León G, Lomonte B, Angulo Y (2011). Antivenoms for Snakebite Envenomings. Inflammation and Allergy. Drug Targets 10(5), 369–80.
[3] Warrell D, Gutierrez JM, Padilla A (2007). Rabies and Envenomings: a Neglected Public Health Issue: Report of a Consultative Meeting. World Health Organization, Geneva.

FIND US AT

Mail Facebook Twitter
DTU BIOBUILDERS
DENMARK
DTU - SØLTOFTS PLADS, BYGN. 221/006
2800 KGS. LYNGBY

MAIN SPONSORS

Lundbeck fundation DTU blue dot